Bayer AG successfully placed new shares at Euro per share
|
|
- Ralph Jennings
- 6 years ago
- Views:
Transcription
1 Ad-hoc-Report according to 15 WpHG Investor Relations Leverkusen Not for distribution in or into the United States of America, Australia, Canada, United Kingdom or Japan successfully placed new shares at Euro per share Leverkusen, July 6, 2006 Issue proceeds of approximately EUR 1.2 billion Significant demand for the new shares from institutional investors Leverkusen today successfully placed 34 million new shares with German and international institutional investors by means of an accelerated bookbuilding. The order book was closed after a few hours due to high demand. The issue price of the new shares amounts to EUR per share, resulting in issue proceeds of approximately EUR 1.2 billion. The total number of shares issued will increase to 764,341,920 once the capital increase has been entered in the commercial register. This capital increase against cash, equivalent to 4.7 percent of the registered share capital, has been approved by the Supervisory Board and is based on the authorisation granted by the Annual Stockholders Meeting on April 28, 2006 (Authorised Capital II). The new shares are fully entitled to the dividend for the current financial year and will be issued without pre-emptive rights for existing stockholders. This transaction, together with the successful EUR 2.3 billion issue of mandatory convertible bonds in April 2006, completes the previously communicated equity financing in connection with the acquisition of Schering. The total equity issuance of EUR 3.5 billion is significantly below the EUR 4 billion limit originally stated
2 - 2 - Board of Management D Leverkusen ISIN: DE WKN: Listing: Official market Frankfurt sub-segment entailing additional post-admission obligations (Prime Standard) Berlin-Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart; Swiss Exchange; London; Madrid; New York, Tokyo Bayer Investor Relations contacts: Dr. Alexander Rosar ( ) Dr. Juergen Beunink ( ) Peter Dahlhoff ( ) Ilia Kürten ( ) Ute Menke ( ) Judith Nestmann ( ) Important Information This announcement contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in the annual and interim reports of to the Frankfurt Stock Exchange and in our reports filed with the SEC. does not assume any liability whatsoever to update these forward-looking statements or to conform them to future events or developments. This announcement may not be distributed, directly or indirectly, in or into the United States, Canada, Australia or Japan. This announcement does not constitute or form part of an offer to sell or issue, or any solicitation of an offer to buy or subscribe for, any securities referred to herein. The placement of shares and the distribution of this announcement and other information in connection with the placement in certain jurisdictions may be restricted by law and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. Any securities referred to in this announcement have not been and will not be registered under the US Securities Act of 1933 (the "Securities Act"), and may not be offered or sold in the United States unless they are registered under the Securities Act or pursuant to an available exemption therefrom. No public offering of securities of the Company is being made in the United States. This communication is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ( Order ) or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as relevant persons ). The Shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise - 3 -
3 - 3 - acquire such Shares will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. This announcement is not an offer of securities for sale in and is not a listing prospectus according to the German Securities Prospectus Act (Wertpapierprospektgesetz) as amended, the Commission Regulation (EC) No 809/2004 of 29 April 2004 as amended, or any other laws applicable in governing the issue, offering and sale of securities.
4 Ad-hoc-Report according to 15 WpHG Investor Relations Leverkusen Not for distribution in or into the United States of America, Australia, Canada, United Kingdom or Japan Bayer issues 34 million new shares Leverkusen, July 6, 2006 Offering part of the financing of the Schering acquisition Placement of the new shares by means of an accelerated bookbuilding Leverkusen is today offering 34 million new shares by means of an accelerated bookbuilding. This offering is one of the previously announced steps to finance the Schering acquisition. The resulting capital increase against cash, equivalent to 4.7 percent of the registered share capital, has been approved by the Supervisory Board and is based on the authorisation granted by the Annual Stockholders Meeting on April 28, 2006 (Authorised Capital II). The new shares are fully entitled to the dividend for the current financial year and will be issued without pre-emptive rights for existing stockholders. The placement of the new shares by means of an accelerated bookbuilding is exclusively directed to German and international institutional investors and is expected to be completed in the course of today. The proceeds of the issue will be announced after pricing and will contribute to the financing of the Schering acquisition. This transaction, together with the successful EUR 2.3 billion issue of mandatory convertible bonds in April 2006, completes the previously communicated equity financing in connection with the acquisition of Schering. The total is significantly below the EUR 4 billion equity financing limit originally stated
5 - 2 - Board of Management D Leverkusen ISIN: DE WKN: Listing: Official market Frankfurt sub-segment entailing additional post-admission obligations (Prime Standard) Berlin-Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart; Swiss Exchange; London; Madrid; New York, Tokyo Bayer Investor Relations contacts: Dr. Alexander Rosar ( ) Dr. Juergen Beunink ( ) Peter Dahlhoff ( ) Ilia Kürten ( ) Ute Menke ( ) Judith Nestmann ( ) Important Information This announcement contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in the annual and interim reports of to the Frankfurt Stock Exchange and in our reports filed with the SEC. does not assume any liability whatsoever to update these forward-looking statements or to conform them to future events or developments. This announcement may not be distributed, directly or indirectly, in or into the United States, Canada, Australia or Japan. This announcement does not constitute or form part of an offer to sell or issue, or any solicitation of an offer to buy or subscribe for, any securities referred to herein. The placement of shares and the distribution of this announcement and other information in connection with the placement in certain jurisdictions may be restricted by law and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. Any securities referred to in this announcement have not been and will not be registered under the US Securities Act of 1933 (the "Securities Act"), and may not be offered or sold in the United States unless they are registered under the Securities Act or pursuant to an available exemption therefrom. No public offering of securities of the Company is being made in the United States. This communication is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ( Order ) or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as relevant persons ). The Shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise - 3 -
6 - 3 - acquire such Shares will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. This announcement is not an offer of securities for sale in and is not a listing prospectus according to the German Securities Prospectus Act (Wertpapierprospektgesetz) as amended, the Commission Regulation (EC) No 809/2004 of 29 April 2004 as amended, or any other laws applicable in governing the issue, offering and sale of securities.
7 Ad-hoc-Report according to 15 WpHG Investor Relations Leverkusen Bayer to sell diagnostics business to Siemens for EUR 4.2 billion Leverkusen, June 29, 2006 Bayer Diabetes Care Division and Schering contrast agents business not affected Decision not driven by financing of Schering acquisition Leverkusen The Bayer Group plans to sell the Diagnostics Division of Bayer HealthCare to Siemens AG, Munich,, for EUR 4.2 billion. The divestment was approved today by the Bayer Supervisory Board. This decision is fully in line with the company s strategy for systematically aligning its health care business. Bayer is concentrating on pharmaceuticals for both humans and animals, and products that can be promoted directly to patients. The systems business of the Diagnostics Division, with its emphasis on hardware, IT networking and comprehensive equipment service, is subject to different success factors than the other Bayer HealthCare divisions. Bayer is therefore divesting these activities as part of the consolidation phase in the diagnostics market. The company is convinced that the successful laboratory equipment business has even better long-term development prospects in a company specializing in medical technology. Closing of the transaction is expected for the first half of 2007, subject to the approval of the antitrust authorities. The consumer-influenced Diabetes Care Division is not affected by the transaction, nor is the contrast agents (diagnostic imaging) business of Schering AG, which will form an important part of the future Bayer Schering Pharma AG
8 - 2 - For Bayer the after-tax proceeds of the divestment will be about EUR 3.6 billion. Although this transaction has been pursued irrespective of the Schering acquisition and its financing, it will affect it in that the planned EUR 1.3 billion hybrid bond may not be launched or may have a much smaller volume. In addition, the previously announced equity raising of up to EUR 4 billion in connection with the Schering acquisition is now likely to be reduced by EUR 500 million. In March this year Bayer had already issued a mandatory convertible bond in the amount of EUR 2.3 billion as a first step. The effect of the divestment is to substantially reduce the company s debt, thus helping to improve its credit profile. Sales of Bayer HealthCare Diagnostics rose in 2005 by 8.4 percent to EUR 1.4 billion. The division employs more than 5,000 people worldwide. It offers an extensive portfolio of in-vitro diagnostic products for evaluating and monitoring the therapy of numerous diseases, including cardiovascular disorders, kidney diseases, infections, cancer and diabetes. Board of Management D Leverkusen ISIN: DE WKN: Listing: Official market Frankfurt sub-segment entailing additional post-admission obligations (Prime Standard) Berlin-Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart; Swiss Exchange; London; Madrid; New York, Tokyo Bayer Investor Relations contacts: Dr. Alexander Rosar ( ) Dr. Juergen Beunink ( ) Peter Dahlhoff ( ) Ilia Kürten ( ) Ute Menke ( ) Judith Nestmann ( ) - 3 -
9 - 3 - Forward-looking statements This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our annual and interim reports to the Frankfurt Stock Exchange and in our reports filed with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
10 Ad-hoc-Report according to 15 WpHG Investor Relations Leverkusen Bayer: Takeover offer for Schering successful Leverkusen, June 20, 2006 Bayer now controls 88.0 percent of issued and outstanding Schering shares Additional acceptance period will run from June 23 to July 6, 2006 The way is now clear for the Bayer Group to acquire Berlin-based pharmaceuticals company Schering AG. Bayer has gained control of a total of 88.0 percent of Schering s approximately 191 million issued and outstanding shares. The attainment of a three-quarters majority was the last remaining condition of the takeover offer. Both the E.U. Commission and the U.S. antitrust authorities had already given their unconditional approval. By the expiration of the acceptance period on June 14, 2006, 87.3 million Schering shares had been tendered to Bayer under the takeover offer. This is equivalent to 45.7 percent of the issued and outstanding Schering shares. In addition, by the same date, Bayer had acquired 77.8 million Schering shares, or 40.7 percent of the issued and outstanding Schering shares, either on the stock market or directly. The minimum acceptance threshold of 75 percent was therefore exceeded. A further 2.9 million Schering shares, or 1.5 percent, were purchased by the Bayer Group thereafter. The remaining Schering stockholders have the opportunity to accept the attractive offer of EUR 89 per share during the additional acceptance period, which runs from June 23 until July 6, Bayer continues to pursue its goal of wholly acquiring Schering. Board of Management - 2 -
11 - 2 - D Leverkusen ISIN: DE WKN: Listing: Official market Frankfurt sub-segment entailing additional post-admission obligations (Prime Standard) Berlin-Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart; Swiss Exchange; London; Madrid; New York, Tokyo Bayer Investor Relations contacts: Dr. Alexander Rosar ( ) Dr. Juergen Beunink ( ) Peter Dahlhoff ( ) Ilia Kürten ( ) Ute Menke ( ) Judith Nestmann ( ) Important information: This is neither an offer to purchase nor a solicitation of an offer to sell shares or American depositary shares of Schering AG. The offer has been made by Dritte BV GmbH, a wholly-owned subsidiary of, for all bearer shares with no par value of Schering AG (including all bearer shares with no par value represented by American depository shares). The terms and conditions of the offer, including any possible extension of the acceptance period in case of a competing offer by a third party, have been published in the offer document after the permission of the German Federal Financial Supervisory Authority (Bundesanstalt fur Finanzdienstleistungsaufsicht, BaFin) has been obtained on April 12, Dritte BV GmbH also has filed a tender offer statement with the U.S. Securities Exchange Commission (SEC) with respect to the takeover offer. Investors and holders of shares and American depositary shares of Schering AG are strongly advised to read the tender offer statement and other relevant documents regarding the takeover offer filed by Dritte BV GmbH with the SEC because they contain important information. Investors and holders of shares and American depositary shares of Schering AG will be able to receive these documents free of charge at the SEC s web site ( or at the web site This is not an offer of s securities for sale in the United States. No such securities have been registered under the U.S. Securities Act of 1933, as amended, and no such securities may be offered or sold in the United States absent registration or an exemption from registration. Any public offering of securities to be made in the United States must be made by means of a prospectus that contains detailed information about the issuer, its management and its financial statements. has been granted exemptive relief from the provisions of Rule 14e-5 under the U.S. Securities Exchange Act of 1934, as amended, permitting it (or Dritte BV GmbH or certain of its other affiliates or financial institutions on its behalf) to make purchases of shares of Schering AG outside of the takeover offer until the end of the offer period, subject to certain conditions. Accordingly, to the extent permissible under applicable securities laws and in accordance with normal German market practice,, Dritte BV GmbH or its nominees or its brokers (acting as agents) may from time to time make certain purchases of, or arrangements to purchase, shares of Schering AG outside the United States, other than pursuant to the offer, before or during the period in which the offer is open for acceptance. These purchases may occur either in the open market at prevailing prices or in private transactions at negotiated prices. Any information about such purchases will be disclosed as required by applicable securities laws
12 - 3 - The distribution of this announcement and the offer and sale of the securities described in this announcement in certain jurisdictions may be restricted by law. Any persons reading this announcement should inform themselves of and observe any such restrictions. This announcement may not be taken, distributed or transmitted, directly or indirectly, in any form in or into Italy or Canada. This communication is directed only at persons who (i) are outside Italy, the United Kingdom, Canada or Japan or (ii) have professional experience in matters relating to investments or (iii) are persons falling within Article 49 (2)(a) to (d) ( high net worth companies, unincorporated associations etc ) of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (all such persons together being referred to as relevant persons ). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. This announcement is not an offer of securities for sale in and is not a listing prospectus according to the German Securities Prospectus Act (Wertpapierprospektgesetz) as amended, the Commission Regulation (EC) No 809/2004 of 29 April 2004 as amended, or any other laws applicable in governing the issue, offering and sale of securities. Any investment decisions or advices for investment decisions should only be made or given based on a prospectus which also includes a section on risk factors.
13 Ad-hoc-Report according to 15 WpHG Investor Relations Leverkusen Merck offers Bayer its stake in Schering Leverkusen, June 14, 2006 Successful acquisition of Schering by Bayer now much more likely Wenning: All three companies concerned will benefit from this step Suit filed against Merck to be withdrawn is to acquire all the shares of Schering held by Merck. In the course of joint talks, Bayer and Merck have agreed on the need to end the uncertainty regarding the Berlin company s future to avoid damaging. Merck has therefore decided to sell its 21.8 percent (according to SEC) stake to Bayer, thereby clearing the way for Bayer s acquisition of Schering. The purchase price is EUR 89 per share. All other Schering stockholders who have tendered their shares under the public takeover offer, or who decide to do so before the acceptance period expires at midnight CEST on Wednesday, will benefit from this price, which is EUR 3 above the original offer. We re very pleased about Merck s decision, because a lengthy competitive bidding process would have greatly affected Schering s future, said Bayer Management Board Chairman Werner Wenning. All three companies concerned will benefit from this step. We are very optimistic that we can now secure at least the three-quarters of Schering s capital stock that we were aiming for, enabling us to quickly begin the integration process. Today we have taken a major step toward creating a world-class German pharmaceutical company. The future company Bayer Schering Pharma will strengthen s role as a pharmaceutical industry location. This is in the interests of the entire sector. Bayer and Merck therefore agreed during their talks to look into further possible opportunities for cooperation between the two companies
14 - 2 - Bayer will withdraw the suit filed against Merck in New York on Tuesday. Board of Management D Leverkusen ISIN: DE WKN: Listing: Official market Frankfurt sub-segment entailing additional post-admission obligations (Prime Standard) Berlin-Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart; Swiss Exchange; London; Madrid; New York, Tokyo Bayer Investor Relations contacts: Dr. Alexander Rosar ( ) Dr. Juergen Beunink ( ) Peter Dahlhoff ( ) Ilia Kürten ( ) Ute Menke ( ) Judith Nestmann ( ) Important information: This is neither an offer to purchase nor a solicitation of an offer to sell shares or American depositary shares of Schering AG. The offer has been made by Dritte BV GmbH, a wholly-owned subsidiary of, for all bearer shares with no par value of Schering AG (including all bearer shares with no par value represented by American depository shares). The terms and conditions of the offer, including any possible extension of the acceptance period in case of a competing offer by a third party, have been published in the offer document after the permission of the German Federal Financial Supervisory Authority (Bundesanstalt fur Finanzdienstleistungsaufsicht, BaFin) has been obtained on April 12, Dritte BV GmbH also has filed a tender offer statement with the U.S. Securities Exchange Commission (SEC) with respect to the takeover offer. Investors and holders of shares and American depositary shares of Schering AG are strongly advised to read the tender offer statement and other relevant documents regarding the takeover offer filed by Dritte BV GmbH with the SEC because they contain important information. Investors and holders of shares and American depositary shares of Schering AG will be able to receive these documents free of charge at the SEC s web site ( or at the web site This is not an offer of s securities for sale in the United States. No such securities have been registered under the U.S. Securities Act of 1933, as amended, and no such securities may be offered or sold in the United States absent registration or an exemption from registration. Any public offering of securities to be made in the United States must be made by means of a prospectus that contains detailed information about the issuer, its management and its financial statements
15 - 3 - has been granted exemptive relief from the provisions of Rule 14e-5 under the U.S. Securities Exchange Act of 1934, as amended, permitting it (or Dritte BV GmbH or certain of its other affiliates or financial institutions on its behalf) to make purchases of shares of Schering AG outside of the takeover offer until the end of the offer period, subject to certain conditions. Accordingly, to the extent permissible under applicable securities laws and in accordance with normal German market practice,, Dritte BV GmbH or its nominees or its brokers (acting as agents) may from time to time make certain purchases of, or arrangements to purchase, shares of Schering AG outside the United States, other than pursuant to the offer, before or during the period in which the offer is open for acceptance. These purchases may occur either in the open market at prevailing prices or in private transactions at negotiated prices. Any information about such purchases will be disclosed as required by applicable securities laws. The distribution of this announcement and the offer and sale of the securities described in this announcement in certain jurisdictions may be restricted by law. Any persons reading this announcement should inform themselves of and observe any such restrictions. This announcement may not be taken, distributed or transmitted, directly or indirectly, in any form in or into Italy, the United States or Canada. This communication is directed only at persons who (i) are outside Italy, the United Kingdom, the United States, Canada or Japan or (ii) have professional experience in matters relating to investments or (iii) are persons falling within Article 49 (2)(a) to (d) ( high net worth companies, unincorporated associations etc ) of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (all such persons together being referred to as relevant persons ). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. This announcement is not an offer of securities for sale in and is not a listing prospectus according to the German Securities Prospectus Act (Wertpapierprospektgesetz) as amended, the Commission Regulation (EC) No 809/2004 of 29 April 2004 as amended, or any other laws applicable in governing the issue, offering and sale of securities. Any investment decisions or advices for investment decisions should only be made or given based on a prospectus which also includes a section on risk factors.
16 Ad-hoc-Report according to 15 WpHG Investor Relations Leverkusen still aims to secure a majority holding in Schering Leverkusen, June 14, 2006 Wenning: We re ready for the second round Mandatory offer to Schering stockholders in preparation Suit for damages filed against Merck for violating U.S. capital market law still aims to wholly acquire Schering AG and is preparing to launch a mandatory offer if the current takeover offer proves unsuccessful. This means Bayer must make a new offer to all Schering stockholders to acquire the shares they still own because Bayer now holds more than 30 percent of Schering stock, purchased at prices of up to EUR 88 per share. This also includes the shares tendered by Allianz. Bayer has chosen this course of action on the assumption that Merck will not tender the shares it now owns under the current takeover offer. The road has gotten rougher, but we re not losing sight of the clear aim we set ourselves: our plan is to combine our pharmaceutical activities with those of Schering to form a world-class German pharmaceutical company, said Bayer Management Board Chairman Werner Wenning. We will do everything we can to clarify the situation as quickly as possible and prevent Merck s tactics from harming the future development of the successful company Schering. The Bayer CEO again made it clear that his company places great importance on preserving Schering, its tradition-rich name and its location in the German capital Berlin. We will continue to put up a good, fair fight for Schering because we are convinced that together we can create value from which everyone benefits: Schering, Bayer and our stockholders, and also as a location for the pharmaceutical industry, said Wenning. In addition, Bayer filed suit for damages against Merck on Tuesday in New York. The effect of Merck s tactics has been to withhold important information from the financial markets, putting Schering stockholders at a disadvantage and harming Bayer, explained General Counsel Dr. Roland Hartwig. He said Merck - 2 -
17 - 2 - had failed to disclose its strategic intentions in violation of U.S. law, thus leaving investors and the parties to the takeover uncertain as to that company s objectives. Merck s dubious tactics are illustrated by the sequence of events: on March 23 Bayer announced its friendly takeover offer, which has the support of both the Management Board and the Supervisory Board of Schering and exceeds Merck s hostile takeover bid by 12 percent. A few hours after Bayer s announcement, Merck declared its withdrawal from the bidding, both publicly and also in a letter to the Bayer Management Board Chairman, saying one of its reasons for doing so was that the price of EUR 86 could not be justified. Then, however, toward the end of the acceptance period for Bayer s offer, Merck purchased huge numbers of Schering shares at prices similar to the offer price without enlightening the financial markets as to the background to this action. Thus Merck concealed from the public its true intentions as an additional bidder. First signaling a withdrawal and then reviving its bid without proper explanation violates both the letter and the spirit of capital market law. By not announcing its intentions in purchasing the shares, Merck has failed to comply with the requirements of the U.S. capital market, explained Hartwig. Board of Management D Leverkusen ISIN: DE WKN: Listing: Official market Frankfurt sub-segment entailing additional post-admission obligations (Prime Standard) Berlin-Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart; Swiss Exchange; London; Madrid; New York Bayer Investor Relations contacts: Dr. Alexander Rosar ( ) Dr. Juergen Beunink ( ) Peter Dahlhoff ( ) Ilia Kürten ( ) Ute Menke ( ) Judith Nestmann ( ) - 3 -
18 - 3 - Important Information: This is neither an offer to purchase nor a solicitation of an offer to sell shares or American depositary shares of Schering AG. The offer has been made by Dritte BV GmbH, a wholly-owned subsidiary of, for all bearer shares with no par value of Schering AG (including all bearer shares with no par value represented by American depository shares). The terms and conditions of the offer, including any possible extension of the acceptance period in case of a competing offer by a third party, have been published in the offer document after the permission of the German Federal Financial Supervisory Authority (Bundesanstalt fur Finanzdienstleistungsaufsicht, BaFin) has been obtained on April 12, Dritte BV GmbH also has filed a tender offer statement with the U.S. Securities Exchange Commission (SEC) with respect to the takeover offer. Investors and holders of shares and American depositary shares of Schering AG are strongly advised to read the tender offer statement and other relevant documents regarding the takeover offer filed by Dritte BV GmbH with the SEC because they contain important information. Investors and holders of shares and American depositary shares of Schering AG will be able to receive these documents free of charge at the SEC s web site ( or at the web site This is not an offer of s securities for sale in the United States. No such securities have been registered under the U.S. Securities Act of 1933, as amended, and no such securities may be offered or sold in the United States absent registration or an exemption from registration. Any public offering of securities to be made in the United States must be made by means of a prospectus that contains detailed information about the issuer, its management and its financial statements. has been granted exemptive relief from the provisions of Rule 14e-5 under the U.S. Securities Exchange Act of 1934, as amended, permitting it (or Dritte BV GmbH or certain of its other affiliates or financial institutions on its behalf) to make purchases of shares of Schering AG outside of the takeover offer until the end of the offer period, subject to certain conditions. Accordingly, to the extent permissible under applicable securities laws and in accordance with normal German market practice,, Dritte BV GmbH or its nominees or its brokers (acting as agents) may from time to time make certain purchases of, or arrangements to purchase, shares of Schering AG outside the United States, other than pursuant to the offer, before or during the period in which the offer is open for acceptance. These purchases may occur either in the open market at prevailing prices or in private transactions at negotiated prices. Any information about such purchases will be disclosed as required by applicable securities laws. The distribution of this announcement and the offer and sale of the securities described in this announcement in certain jurisdictions may be restricted by law. Any persons reading this announcement should inform themselves of and observe any such restrictions. This announcement may not be taken, distributed or transmitted, directly or indirectly, in any form in or into Italy, the United States or Canada. This communication is directed only at persons who (i) are outside Italy, the United Kingdom, the United States, Canada or Japan or (ii) have professional experience in matters relating to investments or (iii) are persons falling within Article 49 (2)(a) to (d) ( high net worth companies, unincorporated associations etc ) of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (all such persons together being referred to as relevant persons ). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. This announcement is not an offer of securities for sale in and is not a listing prospectus according to the German Securities Prospectus Act (Wertpapierprospektgesetz) as amended, the Commission Regulation (EC) No 809/2004 of 29 April 2004 as amended, or any other laws applicable in governing the issue, offering and sale of securities. Any investment decisions or advices for investment decisions should only be made or given based on a prospectus which also includes a section on risk factors.
19 Ad-hoc-Report according to 15 WpHG Investor Relations Leverkusen Overallotment option for Bayer Mandatory Convertible Bond fully exercised Leverkusen, March 30, 2006 One day after the placement of the Bayer Mandatory Convertible Bond, the overallotment option ( Greenshoe ) of 300 million has been fully exercised. The exercise of the overallotment option by the bookrunners follows the positive reception of the bond in the market. The total size of the transaction including overallotment option is 2.3 billion. Board of Management D Leverkusen ISIN: DE WKN: Listing: Official market Frankfurt sub-segment entailing additional post-admission obligations (Prime Standard) Berlin-Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart; Swiss Exchange; London; Madrid; New York Bayer Investor Relations contacts: Dr. Alexander Rosar ( ) Dr. Juergen Beunink ( ) Peter Dahlhoff ( ) Ilia Kürten ( ) Ute Menke ( ) Judith Nestmann ( ) - 2 -
20 - 2 - Important information This announcement contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in the annual and interim reports of to the Frankfurt Stock Exchange and in our reports filed with the SEC. and Bayer Capital Corporation B.V. do not assume any liability whatsoever to update these forward-looking statements or to conform them to future events or developments. This announcement is for general information only and does not form part of any offer to sell, or the solicitation of any offer to buy, securities. The distribution of this announcement and the offer and sale of the securities described in this announcement in certain jurisdictions may be restricted by law. Any persons reading this announcement should inform themselves of and observe any such restrictions. This announcement may not be taken, distributed or transmitted, directly or indirectly, in any form in or into Italy, the United States, Canada or Japan. This announcement is not an offer of securities for sale in the United States. The offer and sale of the securities referred to in this announcement has not been, nor will it be, registered under the United States Securities Act of 1933 and the securities referred to in this announcement may not be offered or sold in the United States absent such registration or an applicable exemption from registration. There will be no public offer of these securities in the United States This communication is directed only at persons who (i) are outside Italy, the United Kingdom, the United States, Canada or Japan or (ii) have professional experience in matters relating to investments or (iii) are persons falling within Article 49 (2)(a) to (d) ( high net worth companies, unincorporated associations etc ) of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (all such persons together being referred to as relevant persons ). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. This announcement is not an offer of securities for sale in and is not a listing prospectus according to the German Securities Prospectus Act (Wertpapierprospektgesetz) as amended, the Commission Regulation (EC) No 809/2004 of 29 April 2004 as amended, or any other laws applicable in governing the issue, offering and sale of securities. Any investment decisions or advices for investment decisions should only be made or given based on a prospectus which also includes a section on risk factors.
21 Ad-hoc-Report according to 15 WpHG Investor Relations Leverkusen Bayer successfully placed a EUR 2 billion subordinated mandatory convertible bond Leverkusen, March 29, 2006 Bayer Capital Corporation B.V., Mijdrecht has today successfully placed a EUR 2 billion bond, mandatorily convertible into shares of, with institutional investors. The mandatory convertible bond is subordinated and enjoys a subordinated guarantee from., The bond will mandatorily convert into new shares, created from the existing conditional capital of, at maturity in June The mandatory convertible bond will be issued without pre-emptive rights for existing shareholders. The main terms of the mandatory convertible bond include a 6.625% coupon, a minimum conversion price of EUR and a conversion premium of 17%, resulting in a maximum conversion price of EUR The minimum conversion price equals the volume weighted average price of Bayer AG shares from start of trading until pricing of the transaction today. will benefit from an increasing share price up to the maximum conversion price as a lower number of shares will have to be issued on conversion. The net proceeds will be used among others as part of the financing of the intended acquisition of Schering AG and is part of the previously announced equity capital raising measures of up to EUR 4 billion. Board of Management D Leverkusen ISIN: DE WKN:
22 - 2 - Listing: Official market Frankfurt sub-segment entailing additional post-admission obligations (Prime Standard) Berlin-Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart; Swiss Exchange; London; Madrid; New York Bayer Investor Relations contacts: Dr. Alexander Rosar ( ) Dr. Juergen Beunink ( ) Peter Dahlhoff ( ) Ilia Kürten ( ) Ute Menke ( ) Judith Nestmann ( ) Important information This announcement contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in the annual and interim reports of to the Frankfurt Stock Exchange and in our reports filed with the SEC. and Bayer Capital Corporation B.V. do not assume any liability whatsoever to update these forward-looking statements or to conform them to future events or developments. This announcement is for general information only and does not form part of any offer to sell, or the solicitation of any offer to buy, securities. The distribution of this announcement and the offer and sale of the securities described in this announcement in certain jurisdictions may be restricted by law. Any persons reading this announcement should inform themselves of and observe any such restrictions. This announcement may not be taken, distributed or transmitted, directly or indirectly, in any form in or into Italy, the United States, Canada or Japan. This announcement is not an offer of securities for sale in the United States. The offer and sale of the securities referred to in this announcement has not been, nor will it be, registered under the United States Securities Act of 1933 and the securities referred to in this announcement may not be offered or sold in the United States absent such registration or an applicable exemption from registration. There will be no public offer of these securities in the United States This communication is directed only at persons who (i) are outside Italy, the United Kingdom, the United States, Canada or Japan or (ii) have professional experience in matters relating to investments or (iii) are persons falling within Article 49 (2)(a) to (d) ( high net worth companies, unincorporated associations etc ) of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (all such persons together being referred to as relevant persons ). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. This announcement is not an offer of securities for sale in and is not a listing prospectus according to the German Securities Prospectus Act (Wertpapierprospektgesetz) as amended, the Commission Regulation (EC) No 809/2004 of 29 April 2004 as amended, or any other laws applicable in governing the issue, offering and sale of securities. Any investment decisions or advices for investment decisions should only be made or given based on a prospectus which also includes a section on risk factors.
23 Ad-hoc-Report according to 15 WpHG Investor Relations Leverkusen Bayer announces the launch of a EUR 2 billion subordinated mandatory convertible bond Leverkusen, March 29, 2006 The supervisory board authorised the issuance of a EUR 2 billion subordinated bond, mandatorily convertible into shares of, due June The security will be issued by Bayer Capital Corporation B.V., Mijdrecht. The accelerated bookbuilding launched this morning is expected to close during the course of today. The lower conversion price, the coupon and the conversion premium will be determined and announced immediately following pricing of the bond. The issuance volume of EUR 2 billion can be increased by up to EUR 300 million if the overallotment option is exercised. The bond is subordinated and will enjoy a subordinated guarantee from. The bond will mandatorily convert into new shares, created from the existing conditional capital of, at maturity in June The mandatory convertible bond will be issued without pre-emptive rights for existing shareholders. The mandatory convertible bond is expected to carry an annual coupon within a range of 6.25 to 6.75%. It is further expected that the conversion premium on the minimum conversion price will be in the range of 16 20%, which yields then the higher conversion price. will benefit from an increasing share price up to the maximum conversion price as a lower number of shares will have to be issued upon conversion. expects that the bond will receive a high equity credit treatment from rating agencies. The net proceeds will be used among others as part of the financing of the intended acquisition of Schering AG and is part of the previously announced equity capital raising measures of up to EUR 4 billion. The bond will be sold in a private placement to institutional investors outside of the United States of America, Canada, Japan, Australia and Italy only
24 - 2 - In connection with the issuance of the mandatory convertible bond will commit not to issue any further equity capital or bonds convertible into equity capital during a period of 90 days. Board of Management D Leverkusen ISIN: DE WKN: Listing: Official market Frankfurt sub-segment entailing additional post-admission obligations (Prime Standard) Berlin-Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart; Swiss Exchange; London; Madrid; New York Bayer Investor Relations contacts: Dr. Alexander Rosar ( ) Dr. Juergen Beunink ( ) Peter Dahlhoff ( ) Ilia Kürten ( ) Ute Menke ( ) Judith Nestmann ( ) Important information This announcement contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in the annual and interim reports of to the Frankfurt Stock Exchange and in our reports filed with the SEC. and Bayer Capital Corporation B.V. do not assume any liability whatsoever to update these forward-looking statements or to conform them to future events or developments. This announcement is for general information only and does not form part of any offer to sell, or the solicitation of any offer to buy, securities. The distribution of this announcement and the offer and sale of the securities described in this announcement in certain jurisdictions may be restricted by law. Any persons reading this announcement should inform themselves of and observe any such restrictions. This announcement may not be taken, distributed or transmitted, directly or indirectly, in any form in or into Italy, the United States, Canada or Japan. This announcement is not an offer of securities for sale in the United States. The offer and sale of the securities referred to in this announcement has not been, nor will it be, registered under the United States Securities Act of 1933 and the securities referred to in this announcement may not be offered or sold in the United States absent such registration or an applicable exemption from registration. There will be no public offer of these securities in the United States - 3 -
25 - 3 - This communication is directed only at persons who (i) are outside Italy, the United Kingdom, the United States, Canada or Japan or (ii) have professional experience in matters relating to investments or (iii) are persons falling within Article 49 (2)(a) to (d) ( high net worth companies, unincorporated associations etc ) of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (all such persons together being referred to as relevant persons ). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. This announcement is not an offer of securities for sale in and is not a listing prospectus according to the German Securities Prospectus Act (Wertpapierprospektgesetz) as amended, the Commission Regulation (EC) No 809/2004 of 29 April 2004 as amended, or any other laws applicable in governing the issue, offering and sale of securities. Any investment decisions or advices for investment decisions should only be made or given based on a prospectus which also includes a section on risk factors.
Bayer creates a provision in the amount of 275 million euros for civil antitrust actions
Ad-hoc-Report according to 15 WpHG Investor Relations 51368 Leverkusen www.investor.bayer.com Bayer creates a provision in the amount of 275 million euros for civil antitrust actions Leverkusen, December
More informationBayer boosts third-quarter earnings: operating result doubled
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Fall Financial News Conference of Bayer AG Bayer boosts third-quarter earnings: operating result doubled Third-quarter
More informationDr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG:
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG: Innovation is our future 2015 was a very successful
More informationAd hoc announcement Inside information pursuant to Article 17 MAR Heidelberg Pharma AG plans capital measure to fund its ATAC development programs
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT
More informationBayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement Leverkusen, February 11,
More informationPRIMEPULSE prepares for its IPO
PRIMEPULSE prepares for its IPO NOT FOR RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE OR DISTRIBUTION
More informationFor Immediate Release
For Immediate Release Frankfurt am Main 11 March 2018 Deutsche Bank determines price range and offer structure for IPO of DWS DWS shares expected to be offered at a price of between EUR 30.00 to EUR 36.00
More informationEUR 250 million Convertible Bonds due 2020 Convertible into Ordinary Shares of Deutsche Wohnen AG
This is not an offering memorandum or offering circular or prospectus and should not be treated as offering material of any sort and is for information purposes only. NOT FOR DISTRIBUTION IN OR INTO THE
More informationDr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG:
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG: Bayer has outstanding perspectives as a pure
More informationKlöckner & Co SE prices convertible bond offering
Klöckner & Co SE Press Release Date 01-09-2016 Pages 5 Am Silberpalais 1 47057 Duisburg Deutschland Phone: +49 (0) 203-307-2050 Fax: +49 (0) 203-307-5025 E-Mail: pr@kloeckner.com Internet: www.kloeckner.com
More informationNOT FOR DISTRIBUTION TO ANY U.S. PERSON OR IN OR INTO OR TO ANY PERSON LOCATED IN THE UNITED STATES.
Deutsche Übersetzung / German Translation Hinweis: Auf der Internetseite der Emittentin (www.stada.de) ist unter der Rubrik "Investor Relations" unter dem Abschnitt "Anleihen" und dort unter "STADA-EURO-Bond
More informationCEO Werner Baumann at the Annual Stockholders Meeting of Bayer AG:
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com CEO Werner Baumann at the Annual Stockholders Meeting of Bayer AG: Bayer is making good progress strategically
More informationNotice of Annual Shareholders Meeting of Siemens AG on January 30, siemens.com
Notice of Annual Shareholders Meeting 2019 of Siemens AG on January 30, 2019 siemens.com Siemens Aktiengesellschaft Berlin and Munich Notice of Annual Shareholders Meeting 2019 Berlin and Munich, December
More informationQ Analyst and Investor Briefing October 27, 2009
Q3 2009 Analyst and Investor Briefing October 27, 2009 Sales declined by 7.0% to 7,392m (Q3 08: 7,948m); volume -2.8%, price -4.4%, currency +0.6%, portfolio -0.4%. Portfolio and Fx adj. sales dropped
More informationPricing Press Release
Pricing Press Release NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES OF AMERICA, ITALY, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN OR OTHER ANY JURISDICTION IN WHICH OFFERS OR
More informationInvestor News. Another record year for Bayer. Fiscal 2015:
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Fiscal 2015: Another record year for Bayer Focus on the Life Sciences following the successful stock market flotation
More informationPublic Share Purchase Offer. Rocket Internet SE. Charlottenstraße 4, Berlin, Germany. to its shareholders
Public Share Purchase Offer of Rocket Internet SE Charlottenstraße 4, 10969 Berlin, Germany to its shareholders for the acquisition of in the aggregate up to 15,472,912 no-par value bearer shares of Rocket
More informationSanlam Limited. Proposed placing of new ordinary shares to raise up to ZAR 5,700 million
Sanlam Limited Incorporated in the Republic of South Africa Registration number: 1959/001562/06 JSE share code: SLM NSX share code: SLA ISIN: ZAE000070660 ("Sanlam" or the "Company") THIS ANNOUNCEMENT
More informationHelloFresh SE is preparing for its Initial Public Offering
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER
More informationRBPlat is pleased to announce that it has priced and closed the Bookbuild.
ROYAL BAFOKENG PLATINUM LIMITED (Incorporated in the Republic of South Africa) (Registration number 2008/015696/06) JSE share code: RBP ISIN: ZAE000149936 Company code: RBPD Bond code: RBPCB ISIN: ZAE000243853
More information2007 BCSECCOM 249. Applicable British Columbia Provisions Securities Act, R.S.B.C. 1996, c. 418, ss , and 114(2)
April 24, 2007 Headnote Mutual Reliance Review System for Exemptive Relief Applications - Securities Act s. 114(2) Takeover Bids - Exemption from the formal take over bid requirements in Part 13 of the
More informationSteinhoff Africa Retail Limited. (Previously K (South Africa) Proprietary Limited) (Incorporated in the Republic of South Africa)
Steinhoff Africa Retail Limited (Previously K2017221869 (South Africa) Proprietary Limited) (Incorporated in the Republic of South Africa) (Registration number: 2017/221869/06) Share Code: SRR ISIN: ZAE000247995
More informationManagement Board Chairman Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG:
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Management Board Chairman Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG: Bayer has great potential
More informationSupplement No 1. dated 3 November to the. Securities Prospectus. dated 27 October for the public offering of
Supplement No 1 dated 3 November 2016 to the Securities Prospectus dated 27 October 2016 for the public offering of 2,970,000 newly issued no-par value bearer shares (the New Shares ) from the capital
More informationInformation document pursuant to Sec. 4 para. 1 no. 4 WpPG, amended on May 1, 2014*
Information document pursuant to Sec. 4 para. 1 no. 4 WpPG 1/9 E.ON SE Securities Identification No. ENAG99 ISIN CODE: DE000ENAG999 Information document pursuant to Sec. 4 para. 1 no. 4 WpPG, amended on
More informationNon-Deal Debt Roadshow
Science For A Better Life Non-Deal Debt Roadshow Johannes M. Dietsch, Finance Director December 2007 Bayer Non-Deal Debt Roadshow December 2007 Disclaimer This presentation contains forward-looking statements
More informationQ Analyst and Investor Briefing April 29, 2009
Q1 2009 Analyst and Investor Briefing April 29, 2009 Sales declined by 7.5% to 7,895m (Q1 08: 8,536m); Volume -9.4%, price -0.3%, currency +1.9%, portfolio +0.3%. Portfolio and Fx adj. sales dropped by
More informationTryg A/S announces a private placement of shares in relation to the financing of the acquisition of Alka Forsikring
To NASDAQ Copenhagen Announcement no. 20 2017 5 December 2017 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES
More informationas approved by the BaFin on 9 June 2017 in accordance with Section 13 para. 1 German
Supplement H dated 29 May 2018 according to Section 16 para. 1 German Securities Prospectus Act (WpPG) relating to the Base Prospectus for the issuance of Certificates, Warrants and Notes dated 9 June
More informationDeutsche Wohnen Aktiengesellschaft. Frankfurt am Main
English convenience translation Deutsche Wohnen Aktiengesellschaft Frankfurt am Main ISIN DE0006283302 (German Securities No. (WKN) 628330) ISIN DE000A0HN5C6 (German Securities No. (WKN) A0HN5C) Invitation
More informationDr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG:
News Release Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-1 www.news.bayer.com Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer
More informationNOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, OR JAPAN
Launch of an offering of net share settled bonds convertible into new shares and/or exchangeable for existing shares (ORNANEs) due October 1, 2019 in an initial nominal amount of approximately 100 million
More informationInvestor Conference. London, August 6, First Half 2003 Results
Investor Conference London, August 6, 23 First Half 23 Results Safe Harbor This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management.
More informationQ Analyst and Investor Briefing February 26, 2010
Q4 2009 Analyst and Investor Briefing February 26, 2010 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Sales declined by 0.6% to 7,872m (Q4 08: 7,923m); volume 8.2%, price
More informationNOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN
OR JAPAN KLM (together, the Securities ) in the United States or to, or for the account or benefit of, U.S. Persons (as defined in Regulation S under the US Securities Act of 1933, as amended (the Securities
More informationCarrefour launches an offering of US$500 million non-dilutive cash settled convertible bonds
This press release does not constitute or form a part of an offer of or solicitation to purchase securities in the United States of America or to, or for the account or benefit of, U.S. Persons (as defined
More informationFerratum Capital Germany GmbH Berlin, Federal Republic of Germany
Ferratum Capital Germany GmbH Berlin, Federal Republic of Germany Invitation to the holders of the EUR 25,000,000 8.00% Bond 2013/2018 (ISIN DE000A1X3VZ3) and the EUR 20,000,000 4.00% Bond 2017/2018 (ISIN
More informationNot for release, publication, or distribution in the United States of America, Australia, Canada, or Japan MEDIA RELEASE
MEDIA RELEASE DKSH launches IPO on SIX Swiss Exchange DKSH Holding Ltd. Date: March 8, 2012 DKSH Holding Ltd. (DKSH), the leading Market Expansion Services provider with a focus on Asia (1), announces
More informationConvertible Bond Offering
Convertible Bond Offering Released : 13 May 2014 RNS Number : 9157G Primary Health Properties PLC 13 May 2014 News Release NOT FOR DISTRIBUTION IN OR TO THE U.S., CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA
More informationCoca-Cola HBC AG. Coca-Cola HBC AG has received all requisite regulatory approvals for the commencement of the acceptance period
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD VIOLATE THE LAWS OF THAT JURISDICTION
More informationMolecular Partners' IPO bookbuilding resumes with support from Allergan as well as other anchor investors
This is a restricted communication and you must not forward it or its contents to any person to whom forwarding it is prohibited by the legends contained therein. In particular, this release and the information
More informationQ Analyst and Investor Briefing March 3, 2009
Q4 2008 Analyst and Investor Briefing March 3, 2009 Sales declined by 1.5% to 7,923m (Q4 07: 8,040m); Volume -5.7%, price +1.7%, currency +2.0%, portfolio +0.6%. Portfolio and Fx adj. sales dropped by
More informationQ Analyst and Investor Briefing July 31, 2012
Q2 212 Analyst and Investor Briefing July 31, 212 Bayer raises guidance for the full year Strong business performance in the second quarter of 212 Record sales 1.2 billion (+5.% Fx and portfolio adjusted)
More informationPayment Date: 05 June 2015 Valuation Date: 29 November 2016 Coupon Payment: Coupon: 8.4% p.a. Memory Effect Redemption Date: 05 December 2016
Phoenix Autocall Worst of APPLE, GOOGLE USD, 1 Year 6 Months, 8.4% p.a. Coupon with Memory Effect, 30% European Downside Protection, Monthly Redemption Dates INDICATIVE PRODUCT SUMMARY FOR THE INFORMATION
More informationThe nominal amount of the Issue will be 150,000,000, with an increase option of up to 25,000,000, allowing for the incomplete subscription.
Sacyr, S.A. ( Sacyr, the Company or the Issuer ), pursuant to article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council on Market Abuse and article 226 of the Restated Text
More informationGermany Minority Shareholder Rights IBA Corporate and M&A Law Committee 2016
Germany Minority Shareholder Rights IBA Corporate and M&A Law Committee 2016 Contact Frank Thianer P+P Pöllath Frank.Thianer@pplaw.com Contents Page SOURCES OF PROTECTION AND ENFORCEMENT 1 PROTECTION AGAINST
More informationInvestor Q&A. Q: When will the acquisition be completed?
Q: When will the acquisition be completed? Investor Q&A A: The acquisition is expected to be completed in the second quarter of 2017, subject to the satisfaction of certain customary conditions. The following
More informationGRENKELEASING AG Baden-Baden
THESE MATERIALS ARE NOT AN OFFER FOR SALE OF THE SUBSCRIPTION RIGHTS OR THE NEW SHARES REFERRED TO HEREIN IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN, OR IN ANY OTHER JURISDICTION IN WHICH
More informationfor Cash its Notes for offers to purchase table below Old Notes is Purchase Tuesday, Notes (the Purchase accepted for to (but
Government of Jamaica Announces an Invitation for Offers to Purchase for Cash its 2019 Notes, 2021 Notes, 2022 Notes and 2025 Notes KINGSTON, Jamaica, August 8, 2017 Invitation for Offers The Government
More informationTELEFÓNICA, S.A. as provided in article 82 of the Spanish Securities Market Act (Ley del Mercado de Valores), hereby reports the following
RAMIRO SÁNCHEZ DE LERÍN GARCÍA-OVIES Secretario General y del Consejo de Administración TELEFÓNICA, S.A. TELEFÓNICA, S.A. as provided in article 82 of the Spanish Securities Market Act (Ley del Mercado
More informationAroundtown SA. ISIN: LU WKN: A2DW8Z Trading Symbol: AT1 (XETRA) SUBSCRIPTION OFFER
These materials are not an offer or the solicitation of an offer for the sale or subscription of the shares of Aroundtown SA in the United States of America. The subscription rights and the shares referred
More informationBIOPHARMA CREDIT PLC FINAL RESULTS OF THE TENDER OFFERS: APPLICATIONS REPRESENTING SEED ASSETS WITH AN AGGREGATE VALUE OF US$338.
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO ANY US PERSONS OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN, OR ANY OTHER JURISDICTION,
More information2Y Lufthansa Fix Kupon Express Anleihe
General Issuer: 2Y Lufthansa Fix Kupon Express Anleihe Indicative Termsheet 26 November 2018 Commerzbank AG (Moodys A1 / S&P A- / Fitch A- (structured debt instruments)) Commerzbank intends to sell its
More informationIMPORTANT NOTICE NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR TO ANY PERSON OR ADDRESS IN THE U.S.
IMPORTANT NOTICE NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR TO ANY PERSON OR ADDRESS IN THE U.S. IMPORTANT: You must read the following before continuing. The following applies to the Offering Circular
More information2006 BCSECCOM 721. Applicable British Columbia Provisions Securities Act, R.S.B.C. 1996, c. 418, ss , and 114(2) and
November 16, 2006 Headnote Mutual Reliance Review System for Exemptive Relief Applications - Securities Act s. 114(2) Takeover Bids - Exemption from the formal take over bid requirements in Part 13 of
More informationQ Analyst and Investor Briefing July 28, 2011
Q2 211 Analyst and Investor Briefing July 28, 211 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Group sales at 9,252 million, up 5.4% (portfolio and currency adjusted) Price
More informationSupplement No 2. dated 10 November to the. Securities Prospectus. dated 27 October for the public offering of
Supplement No 2 dated 10 November 2016 to the Securities Prospectus dated 27 October 2016 for the public offering of 2,970,000 newly issued no-par value bearer shares (the New Shares ) from the capital
More informationSFC Energy AG. Brunnthal - ISIN DE WKN We hereby invite our shareholders. on Thursday, May 7, 2015 at 10:00 a.m.
This version of the notice of shareholder s meeting, prepared for the convenience of English-speaking readers, is a translation of the German original. For the purposes of interpretation the German text
More informationNotice. of the. Annual Stockholders Meeting
Notice of the Annual Stockholders Meeting of Bayer AG on April 26, 2019 2 Contents Notice of the Annual Stockholders Meeting 2019 Contents Agenda 1. Presentation of the adopted annual financial statements
More informationPress Release Stockholm 2 May 2017 MEDICOVER INTENDS TO LIST ON NASDAQ STOCKHOLM
Press Release Stockholm 2 May 2017 NOT FOR DISTRIBUTION, RELEASE OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
More informationRocket Internet SE Berlin. Invitation to the ordinary General Meeting
Convenience Translation. The German language version shall prevail in the event of any dispute or ambiguity. Rocket Internet SE Berlin Securities Identification Number: A12UKK ISIN: DE000A12UKK6 Invitation
More informationNOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA
RALLYE EUR 200,000,000 5.25 per cent. Non-Dilutive Cash Settled Bonds due 2022 Exchangeable into Existing Shares of Casino, Guichard-Perrachon (the Bonds ) (ISIN code FR0013215415) Capitalised terms not
More informationDresdner Bank Aktiengesellschaft Frankfurt am Main. Base Prospectus. from 22 June for
Dresdner Bank Aktiengesellschaft Frankfurt am Main Base Prospectus from 22 June 2007 for [Number] [Name] [Participation] [Open-End] [ ] Certificates [with Maximum Amount] [with Performance Comparison]
More informationPress release 14 June 2018
This press release may not be published, transmitted or distributed, either directly or indirectly, in the United States, Canada, Australia or Japan. This press release does not constitute an offer for
More informationDEUTSCHE LUFTHANSA AKTIENGESELLSCHAFT
These materials are not an offer or the solicitation of an offer for sale or subscription of the shares in the United States of America. The subscription rights and the shares may not, at any time, be
More informationINTERIM STATEMENT GODEWIND IMMOBILIEN AG 1
INTERIM STATEMENT GODEWIND IMMOBILIEN AG 1 GODEWIND IMMOBILIEN AG FRANKFURT AM MAIN CONSOLIDATED INTERIM STATEMENT IN COMPLIANCE WITH IFRS FOR THE PERIOD 1 JANUARY TO 31 MARCH 2018 The following consolidated
More informationNOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN
CANADA OR JAPAN KLM (together, the Securities ) in the United States or to, or for the account or benefit of, U.S. Persons (as defined in Regulation S under the US Securities Act of 1933, as amended (the
More informationBayer: Operational business held back by currency effects Major progress with Monsanto acquisition
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com First quarter of 2018 Bayer: Operational business held back by currency effects Major progress with Monsanto acquisition
More informationInvestor News. Bayer: strong business momentum continues and portfolio transformation underway. Fiscal 2014:
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Fiscal 2014: Bayer: strong business momentum continues and portfolio transformation underway Group portfolio to
More informationMichelin launches an offering of non-dilutive cash-settled convertible bonds due 2022 for USD 400 million
"No communication or information relating to Michelin s convertible non-dilutive cashsettled bonds issue may be distributed to the public in any jurisdiction in which registration or approval is required,
More informationNOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, OR AUSTRALIA.
This press release does not constitute an offer to sell securities in the United States or in any other jurisdiction. The Bonds (and the underlying shares) may not be offered or sold in the United States
More informationTHE BOARD OF DIRECTORS OF IXONOS PLC HAS DECIDED ON A RIGHTS ISSUE IN A MAXIMUM AMOUNT OF APPROXIMATELY EUR 5.43 MILLION
Not to be published in or distributed to the United States of America, Canada, Australia, Hong Kong, South Africa or Japan THE BOARD OF DIRECTORS OF IXONOS PLC HAS DECIDED ON A RIGHTS ISSUE IN A MAXIMUM
More informationGeneral Meeting Agenda
Contents 01 Presentation of the established Annual Financial Statements and Management Report (including the explanatory report on disclosures pursuant to 289 (4) German Commercial Code) for the 2013 financial
More informationProposed repurchase of outstanding OCEANEs due January 1, 2014 (the 2014 OCEANEs ) via a reverse bookbuilding process
This announcement is not an offer of securities in the United States of America or any other jurisdiction. The Bonds (and underlying shares) may not be offered or sold in the United States of America absent
More informationRepower plans rights issue to increase its capital and acquires two new shareholders with a long-term horizon: EKZ and UBS-CEIS
Poschiavo, 30 May 2016 Repower plans rights issue to increase its capital and acquires two new shareholders with a long-term horizon: EKZ and UBS-CEIS Repower AG is planning a rights issue to increase
More informationADLER Real Estate Aktiengesellschaft Berlin WKN ISIN DE Invitation to 2017 Annual General Meeting
ADLER Real Estate Aktiengesellschaft Berlin WKN 500 800 ISIN DE0005008007 Invitation to 2017 Annual General Meeting Dear Shareholders, You are hereby cordially invited to the Annual General Meeting of
More informationGenoa, 17 November 2017 With regard to the capital increase transaction, the Board
The distribution of this press release, directly or indirectly, in or into the United States, Canada, Australia or Japan is prohibited. This press release (and the information contained herein) does not
More informationExplanatory Report. of the Executive Board. of RWE Aktiengesellschaft
Explanatory Report of the Executive Board of RWE Aktiengesellschaft in accordance with Section 176, Paragraph 1 of the German Stock Corporation Act (AktG) on Takeover-related Issues pursuant to Section
More informationNOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.
This press release is an advertisement and not a prospectus and not an offer of securities for sale to U.S. persons or in any jurisdiction, including in or into the United States, Canada, Japan or Australia.
More information(or one of its subsidiaries, in which case CMA CGM would fully guarantee all such subsidiary's obligations under the public tender offer)
Pre-announcement of the public tender offer of CMA CGM S.A., Marseille, France (or one of its subsidiaries, in which case CMA CGM would fully guarantee all such subsidiary's obligations under the public
More informationInvitation to the 2009 Annual General Meeting. ISIN DE000CLS1001 WKN (German Securities Code) CLS 100
Invitation to the 2009 Annual General Meeting ISIN DE000CLS1001 WKN (German Securities Code) CLS 100 - 2 - Key financial figures: Five-year overview 2004 2005 2006 2007 2008 Earnings position Revenue m
More informationInvitation to the Annual General Meeting 2018 on 3 May 2018
Invitation to the Annual General Meeting 2018 on 3 May 2018 INVITATION TO THE ANNUAL GENERAL MEETING OF LINDE AKTIENGESELLSCHAFT Dear Shareholders, You are invited to attend the Annual General Meeting
More informationBNP PARIBAS (incorporated in France) (as Issuer and Guarantor) BNP PARIBAS ARBITRAGE ISSUANCE B.V. (incorporated in The Netherlands) (as Issuer)
SECOND SUPPLEMENT DATED 12 OCTOBER 2009 TO THE BASE PROSPECTUS DATED 29 MAY 2009 BNP PARIBAS (incorporated in France) (as Issuer and Guarantor) BNP PARIBAS ARBITRAGE ISSUANCE B.V. (incorporated in The
More informationRocket Internet Announces IPO Price Range
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER
More information1/28. Deutsche Beteiligungs AG Frankfurt am Main WKN ISIN DE Agenda for the 2010 Annual Meeting
Deutsche Beteiligungs AG Frankfurt am Main WKN 550 810 ISIN DE0005508105 Agenda for the 2010 Annual Meeting This is a translation of the German Agenda. Please note that only the German text of this Agenda
More informationInternational M&A. - Public Offers of US Companies shopping overseas - Dr. Joachim Rosengarten LL.M. '92
International M&A - Public Offers of US Companies shopping overseas - Dr. Joachim Rosengarten LL.M. '92 Boalt Hall November 1, 2012 Overview (1) I. Set-up II. Issues to be Resolved III. Legal Background
More informationClient Alert. Recent Changes to CONSOB Rules on Cash Tender Offers and Exchange Offers for Debt Securities Extended into Italy
Number 1230 6 September 2011 Client Alert Latham & Watkins Corporate Department Recent Changes to CONSOB Rules on Cash Tender Offers and Exchange Offers for Debt Securities Extended into Italy Recent changes
More informationDaimler AG and Rolls-Royce launch their public tender offer for Tognum AG; acceptance period begins.
Daimler AG and Rolls-Royce launch their public tender offer for Tognum AG; acceptance period begins. Investor Relations Release Date: April 6, 2011 Tognum shareholders can tender shares from today until
More informationGalenica launches IPO of Galenica Santé and sets price range
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN. PRESS RELEASE Date Contact Investor Relations: Felix Burkhard,
More informationGenSight Biologics launches its Initial Public Offering on the regulated market of Euronext in Paris
Press Release GenSight Biologics launches its Initial Public Offering on the regulated market of Euronext in Paris Capital increase of approximately 40 million, which may be increased to a maximum of approximately
More informationDFS Furniture plc. Initial Public Offering Announcement of Price Range
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OF AMERICA OR ANY JURISDICTION WHERE IT IS UNLAWFUL
More informationLegal Update Capital Investment Act
Legal Update Capital Investment Act AIFM-Directive is implemented in Germany by the Capital Investment Act (KAGB) on 22 July 2013 DR. KARLA GUBALKE, LAWYER PARTNER DR. OLIVER ZANDER, LAWYER PARTNER Munich,
More informationJust Retirement Group plc Announcement of Offer Price Offer Price set at 225 Pence per Share
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE
More informationBarrier Reverse Convertible with Participation linked to Nestle, Roche, Zurich Insurance. 1. Product Description. Underlying Information
1 1. Product Description This Barrier Reverse Convertible (the Security ) is a CHF denominated Security linked to the shares of Nestle, Roche and Zurich Insurance (the Underlyings ). The Security offers
More informationStrike Date: 13 April Apr-16 50, FTSE 100, NIKKEI 225, RUSSELL 2000 INDEX
Quanto Phoenix Autocall Worst of EURO STOXX 50, FTSE 100, NIKKEI 225, RUSSELL 2000 INDEX GBP, 6 Years, 7% p.a. Coupon, 40% European Downside Protection, Semi-Annual Redemption Dates INDICATIVE PRODUCT
More informationINVITATION. to the Annual General Meeting of Allianz SE on May 9, 2018
INVITATION to the Annual General Meeting of Allianz SE on May 9, 2018 2 CONTENTS I. AGENDA 1. Presentation of the approved Annual Financial Statements and the approved Consolidated Financial Statements
More informationWEST BROMWICH BUILDING SOCIETY PLANNED LIABILITY MANAGEMENT EXERCISE
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OR ITS TERRITORIES, AUSTRALIA, SOUTH AFRICA, JAPAN OR CANADA OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF
More informationAktiengesellschaft. Registered Office: Stuttgart Otto-Dürr-Strasse 8, Stuttgart - (WKN) ISIN DE Dear Shareholders,
Aktiengesellschaft Registered Office: Stuttgart Otto-Dürr-Strasse 8, 70435 Stuttgart - (WKN) 556 520 - - ISIN DE 0005565204 - Dear Shareholders, You are hereby invited to our 17th Annual Shareholders'
More informationAnnual General Meeting Invitation to the. of Vonovia SE on Thursday, 12 May 2016
Annual General Meeting 2016 1 Invitation to the Annual General Meeting of on Thursday, 12 May 2016 2 Annual General Meeting 2016 Convenience Translation This is a convenience translation of the German
More informationFOR IMMEDIATE RELEASE. Gordon Dadds Group Limited ("Gordon Dadds" or the "Company")
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, JAPAN,
More information